2013 BIO International Convention Super Sessions to Highlight State of the Industry, Global Innovation and the Affordable Care Act
Washington, DC (March 4, 2013) – The 2013 BIO International Convention will feature six diverse Super Sessions highlighting pressing industry topics such as the state of the industry, emerging R&D initiatives between public and private sectors,the future of biotechnology under the Affordable Care Act (ACA) and the future of deal-making and global innovation. Hosted by the Biotechnology Industry Organization (BIO), the Convention, celebrating its 20thanniversary, will take place April 22-25, 2013 at McCormick Place in Chicago, Ill.
“Attendees have come to expect a dynamic group of C-level speakers from major biotechnology and pharmaceutical companies to be featured during our Super Sessions,” said BIO President & CEO Jim Greenwood. “This year’s line-up will not disappoint as it promises to offer insight and valuable advice on the current economic development, key policy issues and major trends that will impact the future of the global industry.”
Super Sessions include:
The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies grapple with these challenges, health care systems are undergoing a fundamental shift toward outcomes and pay-for-performance. The presentation will feature insights from the report’s authors and a panel of industry leaders by presenting key metrics used to measure the industry’s performance — including financial results, venture capital, public markets, M&A, alliances and more.
Sponsored by Ernst & Young
Tuesday, April 23, 10:00 – 11:30 a.m.
Moderated by Glen Giovannetti, Partner and Global Biotechnology Leader, Ernst & Young and Gautam Jaggi, Senior Manager and Editor, Beyond Borders and Progressions, Ernst & Young
Speakers: Brian Edelman, Vice President, Corporate Finance and Investment Banking, Eli Lilly and
Company, John A. Orwin, Chief Executive Officer, Affymax, Inc. and Denise Pollard-Knight, Managing Director, Phase4 Ventures
The presentation will feature highlights from the new annual report, Biotech 2013: Capturing Value. Governments worldwide are facing new pressures to contain healthcare spending and demands to develop reliable and environmentally sustainable sources of food, energy, and industrial products. Participants will learn what innovation looks like in 2013 and how companies will need to think differently about the way they create and capture value in the evolving world of healthcare.
Sponsored by Burrill & Company
Tuesday, April 23, 2:00 – 3:30 p.m.
Speaker: G. Steven Burrill, Chief Executive Officer, Burrill & Company
In order to help accelerate the time and reduce the cost between concept and cure, a number of new R&D initiatives are emerging. These efforts aim to bring medicines to patients faster by facilitating collaboration to solve common challenges encountered during the discovery and development process. This Super Session will focus on several of these recently-created public and private sector partnerships whose goal is to improve the productivity of the biomedical research ecosystem, and will explore how they may provide solutions with meaningful impact for patients worldwide.
Sponsored by Eli Lilly and Company
Tuesday, April 23, 3:45– 5:15 p.m.
Moderated by Margaret Anderson, Executive Director, FasterCures
Speakers: Christopher Austin, MD, Director, National Center for Translational Sciences (NCATS), National Institutes of Health (NIH), Ronald DePinho, MD, President, The University of Texas MD Anderson Cancer Center and Dale Edgar, Lilly Distinguished Research Fellow, Science and Technology Partnerships, LRL, Eli Lilly & Company
The Patient Protection and Affordable Care Act (ACA) of 2010 includes key provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes will impact the biotechnology industry and the future of patient access to needed medicines. This panel will address significant questions concerning the future of biotechnology under ACA and provide insights on what these changes mean for the industry, such as the impact of ACA on patient access to prescription drugs, biologics, and vaccines as well as implications of State decisions on Exchanges, benchmark benefit plans, and Medicaid expansion.
Sponsored by MedImmune
Wednesday, April 24, 10:00 – 11:30 a.m.
Moderated by Peter S. Greenleaf, MedImmune/AstraZeneca
Speakers: Marc Boutin, Executive Vice President and Chief Operating Officer, National Health Council and James Stansel, Partner, Sidley Austin LLP
Since 2007 we have seen a decline in the pipeline deals across biotech. It used to be common to read about the next billion dollar biobuck deal that your neighborhood small biotech struck with pharma. But how often do we read those headlines these days? Post megamerger, post-patent cliff, and post-financial crises, the reality is that large pharma and big biotech have been much harder to entice for small start-ups. This panel will hear from industry leaders behind the next big deals as they discuss the future of deal-making.
In advance of this interactive panel discussion, Campbell Alliance and BIO will present updated findings from two unique forward-looking measures of deal-making in the industry – the Campbell Alliance Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast.
Sponsored by Campbell Alliance
Wednesday, April 24, 2013, 2:00 p.m. – 3:30 p.m.
Moderated by Jeff Stewart, Senior Engagement Manager, Campbell Alliance and David Thomas, Director, Research & Industry Analysis, Biotechnology Industry Organization
Speakers: Bahija Jallal,PhD, Executive Vice President, Research & Development, MedImmune, Roger Pomerantz, MD, F.A.C.P., World Wide Head of Licensing & Acquisitions and Knowledge Management, Senior Vice President, Merck Research Laboratories
Which countries are winning the innovation game? Will the U.S. maintain its leadership position in the future? Have emerging markets lived up to the hype? Which new partnerships are transforming industries?
The annual Scientific American Worldview session will hear from a dynamic panel of international industry luminaries who plan to examine the future of global innovation in a lively conversation.
The event will explore key themesfrom Scientific American’s annual biotechnology edition, featuring the Worldview Scorecard and fresh perspectives on international life science development.The session will also feature a one-on-one interview with Fareed Zakaria and Trevor Mundel, President, Global Health Program, Bill & Melinda Gates Foundation.
Sponsored by AbbVie
Wednesday, April 24, 3:45 – 5:15 p.m.
Moderator: Fareed Zakaria, CNN host, Editor-at-Large of TIME Magazine, Washington Post columnist, and New York Times bestselling author
Speaker: Trevor Mundel, President, Global Health Program, Bill & Melinda Gates Foundation
The BIO International Convention also features the industry's largest partnering event, hosting a record breaking 25,000+partnering meetings in 2012. More than 4,000 companies participated in One-on-One Partnering meetings in the BIO Business Forum™ and in the BIO Exhibition. These efficient meetings foster the opportunity for companies to initiate business contacts in a friendly environment and schedule meetings prior to the Convention.
Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials. To register, please visit here.